Not Yet RecruitingNot Applicable

A Study to Evaluate Guideline Adoption Through Quality Improvement Project (QIP) in Pulmonary and Critical Care Medicine (PCCM) Department

1,728 participantsStarted 2025-03-01

Plain-language summary

This is a cluster randomized controlled trial with PCCM department in each site being the cluster. Fifty-four sites' PCCM departments will be randomized to the QIP arm versus control arm in 2:1 allocation ratio. The QIP arm will perform QIP intervention. The control arm will not receive intervention and continue with usual care. The primary endpoints of this study are molecular testing rate of non-small cell lung cancer (NSCLC) prior to the first systematic anti-tumor therapy, and adjuvant or first line targeted therapy treatment rate in actionable oncogenic alterations (AGA) NSCLC.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓.1.3 PCCM department who want to improve lung cancer healthcare quality and agree to participate in study.

Exclusion criteria

✕. Individual Patient 2.1 Individual inclusion criteria 2.1.1 Pathology diagnosed NSCLC or ES-SCLC. 2.1.2 No prior systematic anti-tumor therapy, or prior adjuvant and neo-adjuvant therapies, definitive radiation/chemoradiation are permitted as long as treatment was completed at least 12 months prior to the development of recurrent disease.
✕.1.3 Performance score (PS) 0-2. 2.1.4 Life expectancy \>12 weeks. 2.2 Individual exclusion criteria 2.2.1 Have a plan to transfer to other hospitals to receive anti-tumor therapy within 3 months after signing the ICF.
✕.2.2 Participating in another interventional clinical study.

What they're measuring

Molecular testing rate of NSCLC(Non-small cell lung cancer) prior to the first systematic anti-tumor therapy

Timeframe: Baseline, 3/6/12/21/30 months post enrollment

Adjuvant or first line targeted therapy treatment rate in AGA(Actionable oncogenic alterations) NSCLC(Non-small cell lung cancer)

Timeframe: Baseline, 3/6/12/21/30 months post enrollment

Trial details

NCT IDNCT06484972

SponsorChina-Japan Friendship Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-03-31

Contact for this trial

Yanhong Ren, M.D

+86 134 6638 0716 ryhong7561@sina.com

View on ClinicalTrials.gov More Lung Cancer trials

Plain-language summary

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓.1.3 PCCM department who want to improve lung cancer healthcare quality and agree to participate in study.

Exclusion criteria

✕. Individual Patient 2.1 Individual inclusion criteria 2.1.1 Pathology diagnosed NSCLC or ES-SCLC. 2.1.2 No prior systematic anti-tumor therapy, or prior adjuvant and neo-adjuvant therapies, definitive radiation/chemoradiation are permitted as long as treatment was completed at least 12 months prior to the development of recurrent disease.
✕.1.3 Performance score (PS) 0-2. 2.1.4 Life expectancy \>12 weeks. 2.2 Individual exclusion criteria 2.2.1 Have a plan to transfer to other hospitals to receive anti-tumor therapy within 3 months after signing the ICF.
✕.2.2 Participating in another interventional clinical study.

What they're measuring

Molecular testing rate of NSCLC(Non-small cell lung cancer) prior to the first systematic anti-tumor therapy

Timeframe: Baseline, 3/6/12/21/30 months post enrollment

Adjuvant or first line targeted therapy treatment rate in AGA(Actionable oncogenic alterations) NSCLC(Non-small cell lung cancer)

Timeframe: Baseline, 3/6/12/21/30 months post enrollment